Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

开始日期2026-08-01

申办/合作机构-

NCT06693752

/ Recruiting临床2期IIT

Pilot Study of Improved Diagnosis and Monitoring of Hydrocephalus in Neonates and Infants Using Contrast-Enhanced Ultrasound

Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion via placement of an invasive ventricular shunt to relieve elevated intracranial pressure (ICP). The clinical decision for CSF diversion is based on the ventricular size and clinical symptoms which are not robust indicators of brain health in neonatal hydrocephalus. The purpose of this study is to assess the safety and feasibility of performing brain contrast-enhanced ultrasound (CEUS) in neonates and infants with diagnosed and/or suspected hydrocephalus.

开始日期2025-10-01

申办/合作机构

The Children's Hospital of Philadelphia

CTRI/2025/04/085276

/ Not yet recruitingN/AIIT

Comparative Evaluation of the Antimicrobial Efficacy of Fluoride Varnish with Xylitol and Fluoride Varnish with CPP-ACP in children with Early Childhood Caries : A Randomized Clinical Study. - NIL

开始日期2025-07-15

申办/合作机构-

100 项与六氟化硫相关的临床结果

登录后查看更多信息

100 项与六氟化硫相关的转化医学

登录后查看更多信息

100 项与六氟化硫相关的专利（医药）

登录后查看更多信息

15,039

项与六氟化硫相关的文献（医药）

2025-11-01·INTERNATIONAL JOURNAL OF HEAT AND MASS TRANSFER

Turbulent self-quenching mechanism of high-temperature-gradient arc plasma in a converging–diverging cylinder: a numerical study

作者: Tanaka, Yasunori ; Inada, Yuki ; Shigeta, Masaya

Thermofluid dynamic behaviors of SF₆ and air flows including arc plasma and non-ionized gas in a converging-diverging cylinder were studied numerically.The arc plasma in SF₆ gas was constricted with high temperatures exceeding 20 000 K.It formed a slightly compressible and subsonic flow, whereas the ambient non-ionized gas had temperatures below 1000 K and a compressible flow with island-like supersonic flow zones.The arc plasma in air gas had temperatures lower than 12 000 K and a blurred fringe with a low gradient.The entire fluid region including the plasma formed an incompressible and subsonic flow.The different temperature distributions were attributed to differences of their thermal diffusivities and Reynolds numbersFor the SF₆ flow system, SF₆ mols. dissociated in the arc plasma to seven atoms.They were ionized to their ions and electrons, causing considerably greater volume expansion and generating both forward and backward flows locally.Impingements of those flows occurred locally.The generated vortices conveyed the thermal energy outward.Great degrees of turbulent mixing of the thermal energy occurred with the mass d. fluctuation, which produced outward heat flux much stronger than that produced by either convection or conduction.The arc plasma was quenched effectively.

2025-10-01·International Journal of Clinical Oncology

Survival impact and recurrence prediction using oncologic resectability classification in hepatocellular carcinoma following hepatic resection: a Japanese multi-center study

Article

作者: Morita, Kazutoyo ; Inokuchi, Shoichi ; Harada, Noboru ; Izumi, Takuma ; Higashi, Hidefumi ; Yoshizumi, Tomoharu ; Tomino, Takahiro ; Uchiyama, Hideaki ; Iseda, Norifumi ; Motomura, Takashi ; Minagawa, Ryosuke ; Kayashima, Hiroto ; Yamashita, Yo-Ichi ; Ninomiya, Mizuki ; Utsunomiya, Toru ; Sugimachi, Keishi ; Maeda, Takashi ; Fukuzawa, Kengo ; Tsujita, Eiji ; Toshima, Takeo ; Itoh, Shinji ; Yoshiya, Shohei ; Kimura, Koichi

BACKGROUND:

The oncological criteria of resectability for HCC were reported by the Japanese Expert Consensus 2023. The relationship between classification at recurrence and prognosis is unclear in cases with surgical resection in the initial treatment. Factors that predict recurrence patterns are also unknown.

METHODS:

Data were analyzed retrospectively from 937 patients who underwent hepatic resection for primary HCC at 10 facilities. Kaplan-Meier analyses of overall survival (OS) and recurrence-free survival (RFS) after hepatic resection defined according to resectability classification, resectable (R), borderline resectable (BR) 1, and BR2, were performed. In patients who underwent curative resection for R-HCC, we examined the classification and prognosis at the time of recurrence, as well as the factors associated with BR1 or BR2 recurrence.

RESULTS:

RFS and OS rates were significantly better in the R group than in the BR1 and BR2 groups (P < 0.01). Prognosis was worse in patients whose initial HCC was resected with R and whose recurrence was BR1 or BR2 (P < 0.01). Male sex, α-fetoprotein > 12 ng/dL, Des-γ-carboxy prothrombin > 150 mAU/mL, tumor size > 5 cm, poor differentiation, and microscopic vascular invasion were predictors of BR1 or BR2 recurrence within 2 years after curative resection for R-HCC. We developed a scoring system based on these six factors, which stratified not only prognosis but also recurrence pattern.

CONCLUSIONS:

Our results extend this framework by demonstrating the prognostic significance at the time of recurrence and provide factors to predict high-risk recurrence.

2025-10-01·SEPARATION AND PURIFICATION TECHNOLOGY

Dichloromethane-knitting synthesis of fluorinated porous organic polymers for superior sulfur hexafluoride adsorption and separation

作者: Wang, Enhui ; Li, Lina ; Peng, Yuyue ; Li, Zhiyi ; Lei, Hongliang ; Wang, Youzhi ; Meng, Timur ; Su, Hongmin ; Chaleawlert-umpon, Saowaluk

Sulfur hexafluoride (SF₆), a crucial gas in the power and semiconductor industries, presents significant challenges for recovery and separationThis work reports the synthesis of a series of porous organic polymers (POPs) with high porosity and physicochem. stability via a Lewis acid-catalyzed slow-knitting method.Different fluorinated organic monomers were employed, using dibromomethane (DBrM) as both solvent and electrophilic cross-linker.The resulting DBrM-knitted POPs exhibited BET surface areas up to 1,408.37 m²/g, surpassing those of chloroform-knitted POPs by 53.51-160.26 %.These materials demonstrated superior SF₆ adsorption capacity, tunable via the position of fluorine groups.The optimal material achieved an SF₆ adsorption capacity of 91 mL/g at 273 K and an SF₆/N₂ separation selectivity of 195.70.An optimal pore size of 0.73 nm was identified for SF₆ adsorption and separationThese findings contribute significantly to the development of advanced porous materials for efficient SF₆ recovery.

项与六氟化硫相关的新闻（医药）

2025-08-06

·PRNewswire

Bracco Imaging Receives Regulatory Approval in China for SonoVue® in the Assessment of Fallopian Tube Patency

New indication of SonoVue® supports non-invasive assessment of female infertility through contrast-enhanced ultrasound in China MILAN, Aug. 5, 2025 /PRNewswire/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that its ultrasound contrast agent SonoVue® has been approved by the China's National Medical Products Administration (NMPA) for use in hysterosalpingo contrast sonography (HyCoSy). HyCoSy is a contrast-enhanced ultrasound (CEUS) procedure that helps identifying potential causes of female infertility related to blockage of the fallopian tubes or uterine abnormalities with a high level of diagnostic accuracy (1,2). Fallopian tube conditions, such as blockages, scarring, or other damage, are a leading cause of infertility, contributing to approximately 25–35 percent of cases of infertility among women in China (3). This regulatory approval represents an important milestone in the management of infertility because, unlike laparoscopic assessment of tubal patency with use of a dye, HyCoSy is a non-invasive procedure, and, unlike traditional X-ray hysterosalpingography, HyCosy does not expose to radiation the genital tract of women in their reproductive years (4-6). "The NMPA approval of SonoVue® use with HyCoSy marks an important step in expanding access to non-invasive, radiation-free detection of tubal issues and uterine problems that often cause infertility in women," said Alberto Spinazzi, Chief Medical and Regulatory Officer, Bracco Group. "We strive to provide healthcare professionals in China with solutions that advance standards of care, reflecting our commitment to advancing diagnostic precision and improving the patient experience through contrast-enhanced ultrasound." "We are proud to support China's healthcare priorities through solutions like SonoVue® that may help address important diagnostic needs," said Valtero Canepa, Head of APAC, Bracco Imaging. "This new indication advances Bracco's role in delivering meaningful innovation in support of the Healthy China 2030 initiative, which prioritizes earlier detection, clinical precision, and broader access to reproductive health services." The high diagnostic performance of HyCoSy with SonoVue® has been confirmed by a recent systematic review and meta-analysis of 24 clinical studies (total of 1358 women with infertility and 2661 fallopian tubes). Using laparoscopic chromotubation dye test as the standard of truth for the assessment of fallopian tube patency, the pooled estimates of sensitivity, specificity, and accuracy of HyCoSy with SonoVue® were 93%, 90%, and 96%, respectively (1). Backed by over 20 years of clinical use, SonoVue® is the ultrasound contrast agent with the largest number of approved indications in the largest number of countries worldwide. The newly approved HyCoSy indication reinforces Bracco Imaging's commitment to expanding non-invasive, high-quality diagnostic tools aligned with evolving clinical standards and national health objectives in China and beyond. Qu E, Zhang M, Ju J, Chen Y, Lin X, Zhang X. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. J Ultrasound Med 2023; 42:7-15 Wang T, Dong T, Nie F. Clinical applications, advances, and future directions in hysterosalpingography. Front Med 2025; 12:1537506 Reproductive Health Branch of Chinese Preventive Medicine Association. Chinese Expert Consensus on Holistic Management of Tubal Factor Infertility (2023 edition) [J]. Chinese Journal of Practical Gynecology and Obstetrics 2023; 39:318-324 Roy KK, Gajapathy SR, Rai R, Zangmo R, Das A, Singhal S. Assessment of Tubal Patency with Selective Chromopertubation at Office Hysteroscopy versus Modified Minilaparoscopy in Infertile Women. Gynecol Minim Invasive Ther 2021; 10:159-165 Perisinakis K, Damilakis J, Grammatikakis J, Theocharopoulos N, Gourtsoyiannis N. Radiogenic risks from hysterosalpingography. Eur Radiol 2003; 13:1522-1528 Sulieman A, Theodorou K, Vlychou M, Topaltzikis T, Roundas C, Fezoulidis I, Kappas C. Radiation dose optimisation and risk estimation to patients and staff during hysterosalpingography. Radiat Prot Dosimetry 2008;128:217-226 For additional information about Bracco's products, and for full prescribing information, please visit . About Bracco Imaging Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at . Media Contacts: Bracco Press Contact: Carolina Bargoni Bracco Imaging, Communications Director [email protected] +39 347 5397738 SOURCE Bracco Imaging WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

放射疗法上市批准诊断试剂

2025-07-23

·医脉通

斩获新适应证！注射用六氟化硫微泡赋能HyCoSy技术，助力不孕诊断再升级

近日，博莱科宣布，其超声造影剂注射用六氟化硫微泡（商品名：声诺维）新适应证正式获得国家药品监督管理局（NMPA）批准，用于子宫输卵管超声造影（HyCoSy）检查。此次获批为临床HyCoSy检查提供了安全、高效的造影剂选择，将助力医生更精准地洞察病情，为患者带来更优质的诊疗体验，推动临床实践迈向新台阶。聚焦未满足临床需求，守护女性生育之光不孕是育龄夫妇常见的问题，在中国积极尝试怀孕的夫妇中，不孕的发生率高达25%1。相关数据显示，我国女性不孕年龄标准化患病率（ASPR）为每10万人4144.55例2，预计到2030年，这一数值将达到每10万人5025.56例3。在诸多导致不孕的因素中，输卵管性不孕约占25%~35%4，严重威胁女性生育健康。准确评价不同部位、不同程度的输卵管病变是抉择不孕诊疗策略的决定性参考因素之一5，对于提升治疗效果具有重要意义。在现有输卵管通畅性评估手段中，HyCoSy凭借与X线子宫输卵管造影（HSG）相媲美的精准诊断效能，加之无辐射、无碘过敏风险、可重复、无创伤、潜在疏通粘连功效，以及检查两周后即可尝试怀孕等多重优势，逐渐成为评估输卵管通畅性的一线方法4,5。在超声诊断中，造影剂的选择直接影响检查效果，临床亟需更多准确性与安全性兼顾的造影剂。在此背景下，注射用六氟化硫微泡新适应证的获批可谓恰逢其时，为临床提升输卵管病变评估质量提供了更优解决方案，助力更多育龄女性实现优生优育。高质量循证背书，铸就精准、安全典范注射用六氟化硫微泡冻干粉末辅料由二硬脂酰磷脂酰胆碱（DSPC）、二棕榈磷脂酰甘油钠（DPPG-Na）、棕榈酸、聚乙二醇4000组成，这些成分经过溶解、冷冻、干燥工艺生成空心粉末，再以六氟化硫气体饱和后密封保存，使用时将其与5 ml氯化钠注射液混合，配制成六氟化硫微泡混悬液备用8。基于精密的成分设计与制备工艺，注射用六氟化硫微泡有着优异的诊断效能和良好的安全性，为临床实践提供了可靠保障。在精准诊断方面，一项纳入24项研究、包括1358例女性2661条输卵管的系统综述与荟萃分析结果显示，应用注射用六氟化硫微泡的HyCoSy敏感度为93%[95%置信区间（CI）:90-95%]，特异度为90%（95% CI：87-92%）7，可有效捕捉输卵管的细微病变。在安全性方面，其同样有亮眼的数据。一项纳入46万例患者的大型多中心研究结果显示，在常规增强超声检查的患者群体中，注射用六氟化硫微泡不良事件（AE）的发生率为0.034%（157/463,434，即约万分之三），严重AE的发生率约为0.001%（4/463,434，即约十万分之一）9，充分证实其是一种安全且耐受性良好的药品。凭借扎实的循证医学证据，注射用六氟化硫微泡被《妇科超声造影临床应用指南》纳入推荐，获得权威认可10。此外，值得一提的是，注射用六氟化硫微泡临床应用已超20年。作为全球具有代表性的超声造影剂之一，其适应证广泛，从超声心动图、血管多普勒，到肝脏、乳腺及儿童泌尿道超声，再到如今的HyCoSy新适应证拓展，不断突破应用边界，同时以持续稳定的出色表现，在超声诊断领域积累了深厚的临床信赖。结语此次注射用六氟化硫微泡HyCoSy新适应证的获批，是妇科及生殖诊断领域的重要里程碑。站在新的起点，这款历经岁月打磨的“匠心之作”，将继续以精准与安全为基石，赋能临床诊疗革新，承载着万千家庭的生育希望，在守护人类健康的征途上续写辉煌篇章。参考文献：1.Zhou Z, Zheng D, Wu H, et al. Epidemiology of infertility in China: a population-based study. BJOG. 2018 Mar;125(4):432-441.2.Feng J, Wu Q, Liang Y, et al. Epidemiological characteristics of infertility, 1990-2021, and 15-year forecasts: an analysis based on the global burden of disease study 2021. Reprod Health. 2025 Feb 19;22(1):26. 3.Yu J, Fu Y, Zeng L, et al. Burden of female infertility in China from 1990 to 2019: a temporal trend analysis and forecasting, and comparison with the global level. Sex Health. 2023 Dec;20(6):577-584. 4.中华预防医学会生殖健康分会, 等. 输卵管性不孕全流程管理中国专家共识(2023年版)[J]. 中国实用妇科与产科杂志,2023,39(3):318-324.5.徐子宁, 王瑶婷, 孙娟, 等. 应用子宫输卵管超声造影评估输卵管通畅性：在争议与困境中前行[J]. 中华生殖与避孕杂志,2024(6).6.Maheux-Lacroix S, Boutin A, Moore L, et al. Hysterosalpingosonography for diagnosing tubal occlusion in subfertile women: a systematic review with meta-analysis. Hum Reprod. 2014 May;29(5):953-63.7.Qu E, Zhang M, Ju J, et al. Is Hysterosalpingo-Contrast Sonography (HyCoSy) Using Sulfur Hexafluoride Microbubbles (SonoVue) Sufficient for the Assessment of Fallopian Tube Patency? A Systematic Review and Meta-Analysis. J Ultrasound Med. 2023 Jan;42(1):7-15. 8.林娴, 陈雪松, 刘丽娟, 等. 基于FAERS数据库对超声造影剂注射用六氟化硫微泡上市后药品不良事件的信号挖掘[J]. 临床超声医学杂志,2024(8).9.Shang Y, Xie X, Luo Y, et al. Safety findings after intravenous administration of sulfur hexafluoride microbubbles to 463,434 examinations at 24 centers. Eur Radiol. 2023 Feb;33(2):988-995. 10.中国医师协会超声医师分会妇产学组. 妇科超声造影临床应用指南 [J/OL]. 中华医学超声杂志（电子版）, 2015, 12(2) : 94-98. 撰写：安墨审校：Nia排版：Atai执行：Atai本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

临床研究诊断试剂放射疗法

2025-05-14

·Business Wire

“Clinically compelling” study shows contrast-enhanced ultrasound (CEUS) is safe and saves lives

BOSTON--(BUSINESS WIRE)--A comprehensive new study based on nationwide claims data from more than 11 million patients shows that diagnostic contrast-enhanced ultrasound (CEUS) exams are safe and can lower a patient’s risk of death. The study, posted online today by the Journal of the American Heart Association, found that serious adverse events associated with ultrasound enhancing agents (UEAs) are “uncommon,” occurring in only 1:10,000 cases. This is “an exceptionally strong safety profile,” according to the study’s lead author, Dr. Jordan Strom, Associate Professor of Medicine at Harvard Medical School, Director of the Echocardiography Laboratory at Beth Israel Deaconess Medical Center, and an officer of the International Contrast Ultrasound Society (ICUS). The large, multicenter, nationwide dataset is broadly representative of US healthcare activity, according to the report. The results mirror those published a decade ago and “reassuringly suggest the continued safety of UEAs in practice,” the authors stated. “This clinically compelling study shows that CEUS is very safe, even for our sickest patients, and saves lives,” said Dr. Steven Feinstein, a cardiologist and Co-President of ICUS. CEUS is a reliable and cost-effective diagnostic tool used worldwide to diagnose heart and vascular disease, identify and characterize tumors, monitor chronic gastro-intestinal diseases, evaluate other serious medical conditions and monitor therapy, Dr. Feinstein said. He noted that, unlike contrast agents used for MR or CT, the enhancing agents used in ultrasound exams do not contain dye, create no known risk of kidney damage or brain deposits, and do not expose patients or hospital staff to ionizing radiation. In addition, CEUS exams are often easier on patients, and they provide highly accurate clinical information in real time so that appropriate therapy can be initiated without delay. Dr. Strom said that UEAs are underutilized in North America despite their well-established clinical and economic benefits, and he called upon more medical centers to offer CEUS to their patients. “UEAs can help us get the right diagnosis upfront, reducing unnecessary and costly downstream testing – and that is not only great for patients, it also helps improve health care cost containment and efficiencies, providing a unique win-win opportunity to save money while actually improving clinical care and outcomes,” Dr. Strom added. CEUS is also safe and useful for a wide range of radiology applications, said Dr. Stephanie Wilson, a radiologist at the University of Calgary and Co-President of ICUS. “We use CEUS every day because it safely and consistently provides high resolution images comparable to – and sometimes better than – CT or MR,” Dr. Wilson said. “Many of our patients cannot tolerate CT or MR, especially if they have kidney disease, so for them CEUS may be the only option for advanced imaging,” she added. Key findings of the newly-published study, which covered a four-year period between 2018 and 2022, include: Serious adverse events associated with UEAs were uncommon (occurring in only 1:10,000 administrations). This relatively low risk was similar across brands of UEAs and years of study. This risk also was consistent with findings of older studies. Patients who received UEAs are often sicker than those who don’t receive them. Still, after accounting for differences among individuals, patients who received UEAs had lower risk of death within 2 days of receiving UEAs during an echocardiogram when compared to patients who did not receive UEAs during an echocardiogram. The authors examined rates of anaphylaxis, myocardial infarction, ventricular tachycardia, cardiac arrest or death within 2 days of echocardiograms administered with and without UEAs. The study concluded that the small rate of serious adverse events should be interpreted in the context of higher risks posed by other contrast media and thus should not preclude use. The authors also cautioned that appropriate processes should be in place to mitigate risk and respond urgently to potential anaphylactoid reactions. A smaller study recently suggested that COVID-19 vaccinations may be linked to higher risk of serious adverse events with a single UEA, but the new nationwide analysis found no such link -- regardless of the agent or year of study evaluated, Dr. Strom said. “Our findings should alleviate any residual safety concerns and make a strong case for broader use of UEAs in order to improve patient care and outcomes and save lives,” Dr. Strom said. Three UEAs are currently approved by the US Food and Drug Administration for use in the United States: Definity (Lantheus); Lumason (Bracco Imaging) and Optison (GE Healthcare). ABOUT ICUS: The International Contrast Ultrasound Society (ICUS) is a nonprofit medical society dedicated to advancing the safe and medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care globally. Membership in ICUS is free of charge and there is no fee for ICUS CME-accredited educational programs, newsletters or other resources. To join ICUS and learn more about CEUS, download ICUS Connect and visit the ICUS website (www.icus-society.org).

临床结果

100 项与六氟化硫相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	六氟化硫	V08DA05	DB11104

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乳腺疾病	中国	Bracco International BV	2003-05-23
肝病	中国	Bracco International BV	2003-05-23
膀胱输尿管返流	中国	Bracco International BV	2003-05-23
心血管疾病	欧盟	Bracco International BV	2001-03-26
心血管疾病	冰岛	Bracco International BV	2001-03-26
心血管疾病	列支敦士登	Bracco International BV	2001-03-26
心血管疾病	挪威	Bracco International BV	2001-03-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
缺氧缺血性脑病	临床3期	美国	Bracco Diagnostics, Inc.	2020-12-01
坏死性小肠结肠炎	临床3期	美国	Bracco Diagnostics, Inc.	2020-11-04
先天性心脏缺损	临床3期	美国	Bracco Diagnostics, Inc.	2015-10-01
心脏病	临床3期	美国	Bracco Diagnostics, Inc.	2015-10-01
冠心病	临床3期	美国	Bracco Diagnostics, Inc.	2015-09-24
冠心病	临床3期	加拿大	Bracco Diagnostics, Inc.	2015-09-24
冠心病	临床3期	德国	Bracco Diagnostics, Inc.	2015-09-24
冠心病	临床3期	意大利	Bracco Diagnostics, Inc.	2015-09-24
肝癌	临床3期	美国	Bracco Diagnostics, Inc.	2009-09-01
可见病灶	临床3期	美国	Bracco Diagnostics, Inc.	2009-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03821376 (CTgov)	临床4期	肾细胞癌 \| 肾肿瘤	12	Lumason	蓋憲積願選選積襯醖衊 = 壓蓋餘鏇網淵積鬱築齋鹹選衊餘鬱鹽繭觸網鏇 (鹽鹹鹹衊獵願範鬱願構, 積鏇繭夢製顧廠願蓋艱 ~ 衊鹽繭壓網鹹糧鹹願餘) 更多	-	2024-10-10
NCT04569799 (TACE, CTgov)	临床4期	肝细胞癌	26	Lumason	願夢艱繭製淵簾糧蓋衊 = 壓鹹醖糧糧顧糧網範築醖衊鏇範餘鬱衊顧顧憲 (繭壓積製構鏇齋衊鏇構, 窪齋艱網遞積鬱積襯獵 ~ 夢顧壓鬱廠簾製繭範鬱) 更多	-	2023-11-02
NCT03687502 (CTgov)	临床2期	阑尾炎	37	Sulfur hexafluoride lipid-type A microspheres	鏇壓鹹繭蓋簾簾簾膚壓 = 鏇鬱艱糧憲壓範觸醖襯窪夢廠選選醖艱衊膚築 (淵窪糧網蓋繭廠製夢壓, 窪襯蓋憲選膚簾鏇選鹹 ~ 艱簾壓網廠醖積蓋獵糧) 更多	-	2022-12-01
NCT03235180 (CTgov)	临床4期	克罗恩病	9	Magnetic Resonance Enterography (MRE)+Sulfur Hexafluoride	齋獵鬱餘鏇淵遞選鬱積(構網餘鑰窪網廠齋獵鑰) = 憲夢鬱鬱觸築鹽簾襯鹹憲遞遞觸遞餘膚積鏇餘 (顧簾鑰範糧艱繭選廠鑰, 4.07) 更多	-	2021-11-10
NCT03040323 (CTgov)	临床4期	-	83	Lumason 60.7Mg Powder for Injection (Biopsy With Lumason)	醖願餘鹽觸鹽願壓製鹽(鹽範顧積膚製餘鏇製廠) = 製廠淵構醖淵簾鬱積艱鏇鹹遞衊積鹽醖構顧顧 (觸鹽餘積願衊築鬱鬱蓋, 餘艱願艱衊遞蓋簾膚獵 ~ 鑰夢鹹膚齋蓋醖餘窪鏇) 更多	-	2019-07-24
NCT03040323 (CTgov)	临床4期	-	83	Placebos (Biopsy With Placebos)	醖願餘鹽觸鹽願壓製鹽(鹽範顧積膚製餘鏇製廠) = 齋鑰鑰鬱壓壓簾窪衊網鏇鹹遞衊積鹽醖構顧顧 (觸鹽餘積願衊築鬱鬱蓋, 膚範範壓壓積窪網鏇顧 ~ 鬱繭窪鬱獵網網鬱鏇廠) 更多	-	2019-07-24
NCT02786810 (CTgov)	临床2期	肾脏疾病 \| 泌尿道感染 \| 膀胱输尿管返流 ... 更多	10	Sulfur hexafluoride type-a lipid microspheres	選積願獵築製廠構憲網 = 構製廠窪願壓衊獵鑰艱夢夢簾襯糧網網餘壓淵 (繭繭鏇觸願鹹鏇憲壓襯, 遞選衊廠廠鑰鏇鏇餘網 ~ 壓蓋願範夢簾遞廠鹽顧) 更多	-	2018-04-04
EAN2017	N/A	急性缺血性卒中	-	Alteplase	壓餘願憲衊糧選窪構積(鹹顧繭糧鬱獵廠衊蓋製) = 鬱壓築齋遞製範夢鑰觸觸淵鹹範築窪壓願鬱簾 (齋觸夢鹹窪願獵願鑰鏇 ) 更多	-	2017-07-13
EAN2017	N/A	急性缺血性卒中	-	Tenecteplase	壓餘願憲衊糧選窪構積(鹹顧繭糧鬱獵廠衊蓋製) = 鹹遞鑰鏇願淵壓顧築網觸淵鹹範築窪壓願鬱簾 (齋觸夢鹹窪願獵願鑰鏇 ) 更多	-	2017-07-13
NCT01306292 (CTgov)	临床2期	肺性高血压	36	Placebo (Hypertension Placebo)	範鏇遞獵願遞壓選構願(窪夢繭蓋製齋夢觸築鹹) = 製鏇夢願鹹顧製繭膚構簾願膚鬱膚顧鑰蓋繭夢 (簾壓選獵壓鑰糧醖餘憲, 17.581) 更多	-	2016-02-08
NCT01306292 (CTgov)	临床2期	肺性高血压	36	SonoVue (Hypertension SonoVue)	範鏇遞獵願遞壓選構願(窪夢繭蓋製齋夢觸築鹹) = 糧鬱築夢觸膚獵夢憲製簾願膚鬱膚顧鑰蓋繭夢 (簾壓選獵壓鑰糧醖餘憲, 17.581) 更多	-	2016-02-08